Panzyga (Human Normal Immunoglobulin)

Panzyga is an immunoglobulin replacement product that acts within the humoral immune system to provide passive immunity.

• Primary immunodeficiency diseases (PIDD): restores deficient IgG levels and reduces infection frequency.
• Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, multiple myeloma): supports immune function when endogenous antibody production is compromised.
• Post‑exposure prophylaxis for certain viral infections: provides immediate antibodies to aid viral neutralisation.
• Immune thrombocytopenia (ITP) with secondary hypogammaglobulinemia: helps achieve hemostatic stability.
• Hematopoietic stem‑cell transplantation conditioning: supplies needed immunoglobulins during engraftment.

• Panzyga supplies pooled human IgG antibodies that bind to a broad spectrum of pathogens and toxins. The infused IgG engages Fc receptors on immune cells, modulates complement activation, and provides opsonisation, thereby enhancing pathogen clearance and restoring humoral immunity in patients with antibody deficiencies.

Adverse reactions to Panzyga are primarily related to infusion and immune responses.

Common Side Effects

• Headache
• Fever
• Chills
• Nausea
• Fatigue
• Myalgia

Serious or Rare Side Effects

• Anaphylaxis
• Severe hemolysis
• Acute renal failure
• Thromboembolic events
• Aseptic meningitis
• Severe hypotension

Panzyga should be administered under medical supervision with attention to patient‑specific risk factors.

• Renal function monitoring: assess baseline creatinine and adjust infusion rate in renal impairment.
• Cardiovascular status: monitor blood pressure and heart rate during infusion, especially in patients with cardiac disease.
• History of allergic reactions: evaluate prior responses to blood products before initiating therapy.
• Concomitant immunosuppressants: watch for enhanced infection risk.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other agents that affect immune function or renal clearance.

Major Interactions (Avoid)

• Live vaccines: concurrent administration can reduce vaccine efficacy and increase adverse events.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): increase risk of renal injury.
• High‑dose corticosteroids: may amplify infection susceptibility.
• Anticoagulants: monitor coagulation parameters as immunoglobulin can affect platelet function.
• Rituximab: may alter IgG kinetics and efficacy.
• Diuretics: adjust fluid balance to avoid volume overload during infusion.